

INSIDE THIS ISSUE

RESEARCH FELLOWSHIPS

Reception honored Full-Year Research Fellowship Award winners.

Page 4

INCOMING PRESIDENT

Bruce D. Lindsay, MD, FHRS, addressed initiatives for the coming year.

Page 6

HRS ADVOCACY

Health Policy Committee focused on important member issues.

Page 13

DAY AT A GLANCE

Saturday

Ongoing
Registration, Exhibition, Debates,
Scientific Sessions, Posters

8:00 a.m.–9:30 a.m.
Special Session: Case-based
Tutorials, Core Curricula, Featured
Symposia

8:00 a.m.–9:30 a.m.
Special Session: Highlights of Heart
Rhythm 2007

8:00 a.m.–9:30 a.m.
Special Session: Douglas P. Zipes
Lectureship—Silvia Priori, MD, PhD

10:30 a.m.–11:30 a.m.
Special Session: AFib Summit
Highlights

1:00 p.m.–5:15 p.m./
1:00 p.m.–7:30 p.m.
Special Session: ABIM Board
Recertification Prep Courses

Please note: All events will take place in the convention center, unless otherwise noted.

SAVE PACe: Dual Chamber Minimal Ventricular Pacing Effective

Use of dual chamber minimal ventricular pacing resulted in a 40% reduction in the relative risk of developing persistent atrial fibrillation in the SAVE PACe trial, presented by Michael O. Sweeney, MD, from Brigham and Women's Hospital in Boston.

The trial, which compared dual chamber minimal ventricular pacing with conventional dual chamber pacing (DDDR), was stopped early by the Data Monitoring Committee when the trial met its primary endpoint: time to development of persistent AF.


It is the first prospective study to demonstrate that prevention of ventricular desynchronization using new dual chamber minimal ventricular pacing algorithms can reduce the risk of developing per-

sistent AF compared with DDDR.

SAVE PACe enrolled 1,065 patients (51% women) with sinus

preserve ventricular conduction, and prevent ventricular desynchronization.

Sweeney reported that 68 patients in the DDDR group developed persistent AF vs. 42 patients in the dual chamber minimal ventricular pacing group. Patients in the new dual chamber pacing group also had a lower risk of invasive ablative procedures and hospitalizations for heart failure, and less ventricular pacing.



Michael O. Sweeney, MD, presented results of SAVE PACe, a late-breaking trial, on Friday.

node dysfunction, intact AV conduction, and normal QRS duration; patients were randomized to DDDR or to the new dual chamber pacing that uses new algorithms (Search AV and MVP) designed to prioritize intrinsic AV conduction,

Multidisciplinary Study of ARVD

Task force criteria for identification of arrhythmogenic right ventricular dysplasia (ARVD) may need revision, given the results of a late-breaking study presented here yesterday.

Frank I. Marcus, MD, of the

(LATE-BREAKERS, see page 3)

Society Recognizes Distinguished Contributors

The Heart Rhythm Society's Distinguished Awards recognize those who have made important contributions through science, education, service and pioneering in cardiac pacing and electrophysiology.

This year's winners: Distinguished Scientist Award, D. George Wyse, MD, PhD, FHRS; Distinguished Teacher Award, Paul A. Levine, MD, FHRS; Distinguished Service Award, Michael E. Cain, MD, FHRS; and Pioneer in Cardiac Pacing and Electrophysiology, David G. Benditt, MD, FHRS.

D. George Wyse, MD, PhD, FHRS

The Distinguished Scientist Award recognizes "an individual who has made major contributions to the advancement of scientific knowledge" in the field of cardiac

pacing and electrophysiology.

Dr. Wyse is Emeritus Professor at University of Calgary, Alberta, Canada. Wyse played an integral role in the Cardiac Arrhythmia Suppression Trial (CAST), the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial and the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial.

Wyse has acted as a consultant to several public research funding agencies and has produced over 300 articles in his active research career. He was also the founding coordinator of the Medical Research Council of Canada's Program Grant in Cardiac Electrophysiology at the University of Calgary.

"Dr. Wyse's common sense and understanding of the big picture have

made his scientific contributions applicable to countless patients," said Stephen C. Hammill, MD, Chair of the Awards Subcommittee.

Paul A. Levine, MD, FHRS

The Distinguished Teacher Award honors an individual who has "demonstrated outstanding skills as a teacher" in electrophysiology and pacing.

Levine has had an eminent career at Boston University, where he was director of the pacing program and electrocardiogram lab until 1989, when he became Vice President for Medical Services of at St. Jude Medical's Cardiac Rhythm Management Division (originally Siemens Pacesetter).

Levine maintains appointments (Distinguished, see page 4)



**Visit us at
Booth #245**

Theodore Chow, M.D., FACC
*Electrophysiologist, The Ohio Heart & Vascular Center;
Director, Electrophysiology Research for Carl & Edyth
Linder Clinical Trials Center*

Medicare has issued a National Coverage Decision covering Spectral Analytic Method™ Microvolt T-Wave Alternans™ (MTWA) testing broadly for the evaluation of patients at risk for sudden cardiac death. "I recommend MTWA testing of primary prevention ICD candidates (LVEF ≤ 35%) when:

- The patient is reluctant to undergo ICD implantation without additional proof of risk;
- The patient has a borderline LVEF for ICD qualification; or
- The time horizon for ICD benefit is reduced, for example by significant co-morbidities or advanced age.

Since the great majority of sudden cardiac deaths occur in patients with LVEF above 35%, MTWA testing is also appropriate in my opinion for evaluating these patients when a clinical suspicion for risk is present, for example, syncope or non-sustained ventricular arrhythmias, particularly in those with LV dysfunction and prior myocardial infarction."



ACC/AHA/ESC Class IIa Guideline - Level of Evidence A
REIMBURSEMENT INCLUDES: Medicare, BCBS*, CIGNA, Aetna & Humana

www.cambridgeheart.com
888.226.9283 x600
heartrhythm@cambridgeheart.com

*Check with your local provider.
Microvolt T-Wave Alternans™ and Spectral Analytic Method™ are trademarks of
Cambridge Heart, Inc. Copyright 2007, Inc. All rights reserved.

Gavel Passes to New Leadership at 2007 President's Reception

Incoming President Bruce D. Lindsay, MD, FHRS, officially took office Friday at the Annual Heart Rhythm Society President's Reception, along with the other members of the Society's new leadership.

"I will work to fulfill the mission of the Heart Rhythm Society by working closely with our capable staff," Lindsay said. "If each incoming President sets a new agenda for the organization, the organization tends to zigzag. The role of the President is to provide guidance to the committees and the Board of Trustees as we try to achieve the organization's goals."

Bruce D. Lindsay, MD, FHRS

Lindsay said he plans to focus on budgetary concerns, reimbursement issues, health policy initiatives, and educational programs. He said it is important for the Society to take action regarding the revision of The Centers for Medicare & Medicaid Services codes.

"There are other technologies coming down the line that could be affected by this," he said. "We need appropriate guidelines for coding and reimbursement."

Lindsay said he will also strive to ensure that Society members are get-

ting as much as possible from the dues they pay to the organization.

Lindsay is the Director of the Clinical Electrophysiology Laboratory and a Clinical Professor of Medicine at the Washington University School of Medicine in St.



President Dwight W. Reynolds, MD, FHRS, passed the gavel to Incoming President Bruce D. Lindsay, MD, FHRS, at a ceremony Friday night.

Louis. He is also Director of the Electrophysiology Unit at Barnes-Jewish Hospital.

Other officers

Also assuming their new posts as 2007 HRS officers:

N.A. Mark Estes, III, MD, FHRS is President-Elect. He is a Professor of Medicine at Tufts University School of Medicine and Director of the Cardiac

Arrhythmia Center at New England Medical Center in Boston.

The position of 1st Vice President

will be held by Richard L. Page, MD, FHRS. Page holds the Robert A. Bruce Endowed Chair in Cardiovascular Research and is head of the Division of Cardiology at the University of Washington Medical Center in Seattle.

Douglas L. Packer, MD, FHRS, vacated his position as Treasurer for the Society to assume the responsibilities of 2nd Vice President. Packer is a Professor of Medicine at The Mayo Clinic College of Medicine in Rochester, MN, with a primary specialty in cardiovascular disease.

Susan L. Song, RN, BSN, FHRS will serve as Secretary through May 2009. She is Device Coordinator at Keck School of Medicine, University of Southern California in Los Angeles. She has been a member of the Society since 1980 and has served on many committees. Previously a Trustee for the Society, John P. DiMarco, MD, PhD, FHRS, will serve as Treasurer. He is Professor of Internal Medicine and Director of Electrophysiology Service at the Division of Cardiovascular Medicine at the University of Virginia Health System.

New members of the Board of Trustees include John D. Day, MD; Leonard I. Ganz, MD; and Cynthia M. Tracy, MD. In addition, Gordon F. Tomaselli, MD, FHRS, was reappointed for a second term of two years.

For more on Dr. Lindsay's objectives, please see page 6.

(LATE-BREAKERS, continued from page 1) University of Arizona, said the goal of his study is to establish a North American registry of newly diagnosed patients based on standardized diagnostic test criteria. A second goal is to determine the genetic background of ARVD, a disease involving the right ventricular myocardium.

The study has analyzed and classified 108 probands, or index patients. Data and diagnostic test results - including 12-lead ECG, signal averaged ECG, and 24 hour Holter monitor - were sent from 17 enrolling centers in the United States and Canada. Imaging studies included a 2D echo, cardiac MRI, and right ventricular angiogram. All tests were subsequently interpreted blindly by experts in core labs.

The high rate of difference in classification by the core laboratories of the right ventricular images by echo, MRI, and angiography was an unexpected finding, Marcus said, and was the impetus for his recommendation to revise the task force criteria. "Genetic identification reveals limitations

of the task force criteria," Marcus added. The task force is scheduled to meet at the conclusion of Heart Rhythm 2007.

CONVERT study

Episodic amiodarone therapy pericardioversion was no more effective than continuous amiodarone therapy for rhythm control in the CONVERT study. Isabelle C. Van Gelder, MD, of the University Hospital Maastricht in the Netherlands, said both strategies were effective but more adverse events occurred in the episodic therapy group.

The trial enrolled 206 patients with recurrent AF who were given a 600-mg loading dose of amiodarone daily for four weeks, followed by 200 mg daily. The patients randomized to the episodic group discontinued amiodarone treatment one month postcardioversion and then restarted the therapy pericardioversion if AF recurred.

Patients randomized to the continuous group continued the amiodarone therapy.

At the median follow-up of 1.8

years, there was no significant difference between the two groups in sinus rhythm control; the number of amiodarone-related events was comparable. There were more recurrences of AF and CV in the episodic treatment group and more disease-related events, including hospitalization for heart failure. Quality of life was similar.

J-Rhythm study

If quality of life is a top consideration, a pharmacologic rhythm control strategy for treatment of paroxysmal AF may be more effective than a rate control strategy, said Satoshi Ogawa, MD, PhD, of the Cardiovascular Institute in Tokyo, in a presentation Friday.

The randomized multicenter comparative study evaluated 823 patients with paroxysmal AF. Patients were randomized to either a pharmacological rate or a rhythm control strategy. Both groups continued antithrombotic therapy. Follow-up was a mean of 586 days.

Ogawa said that sinus rhythm was maintained more frequently in the rhythm control group and re-

sulted in a significantly better event-free survival than the rate control strategy. There was, additionally, a significant difference in quality of life scores for those treated with the rhythm control strategy.

ICE-CHIP trial

Sanjeev Saksena, MD, reported results of ICE-CHIP, the first prospective open label, multicenter trial to compare intracardiac echocardiography to transesophageal echo (TEE) in visualization of septal and left atrial pathology that may predispose patients to stroke.

The Euro-American trial included 95 patients with AF; all patients imaged by both modalities for a blinded comparison. All patients underwent an invasive catheterization procedure, including right heart catheterization, and all had undergone a TEE within the previous 48 hours.

Saksena reported a number of differences between the two modalities. One finding was that ICE more readily identified left atrial thrombi, whereas TEE was more effective for left atrial appendage.

(Distinguished, continued from page 1)

at Loma Linda University, where he is a Clinical Professor of Medicine, and at the University of California Los Angeles, where he is a Clinical Associate Professor of Medicine. He is actively involved in the teaching programs at both institutions.

Levine is internationally recognized as a leading expert in pacemakers and ICDs and is a featured speaker at many international forums and symposia. He has written a number of books on cardiac pacing as well as many peer-reviewed journal articles and book chapters.

"Dr. Levine is truly known as a teacher's teacher," Hammill said.

Michael E. Cain, MD, FHRS

The Distinguished Service Award recognizes an individual who "has made outstanding contributions to the Heart Rhythm Society."

Cain recently moved to Buffalo to become the Dean of the School of Medicine and Biomedical Sciences at University of Buf-

falo. Previously, he was the Lewin Professor of Medicine and Director of the Cardiovascular Division at Washington University in St. Louis. He has been a member of the Heart Rhythm Society since 1985. In 1998, he was elected to the Board of Trustees and subsequently served as Secretary, Chair of the

"The Heart Rhythm Society's Distinguished Awards recognize those who have made important contributions through science, education, service, and pioneering in cardiac pacing and electrophysiology."

—Stephen C. Hammill, MD,

2002 Annual Scientific Sessions and President from 2003 to 2004. He also served as Chair of the Positioning Task Force, which led to the Society's new name and logo.

After his presidency, Cain continued to serve HRS in many capacities. He was Chair of the Governance Committee, Presidents Council, International Advisory Council, and the 2005 Strategic

Planning Conference. For the past two years he has served as the North American Co-chair of the International Coalition of Organizations of Pacing and Electrophysiology and is the current Chair of the Publications Committee.

"Michael Cain has worked tirelessly to improve our Society and

Early in his career, Benditt studied sinus node dysfunction, which led to the publication of a seminal article on the significance of secondary pauses after rapid atrial pacing. He went on to establish an internationally renowned program in cardiac electrophysiology at the University of Minnesota, where he is currently a Professor of Medicine and Co-director of the Arrhythmia Center.

Although Benditt has 200 publications to his credit, he is perhaps best known for his contributions to the understanding of syncope. In addition to pioneering the widespread introduction of the tilt table test to clinical practice, he has been a leader in understanding the indications and limitations of medication to treat vaso-vagal syncope. In addition, he was involved in the early introduction and development of rate responsive pacing, physiological pacing and transvenous defibrillation.

"Dr. Benditt's pioneering work in syncope highlights a career devoted to improving patient care," Hammill said.

Heart Rhythm OnDemand™

Heart Rhythm Society
Building the Way of Life

Over 600 Presentations from
Heart Rhythm 2006 and now 2007!

MP3/PDF Conference Companion[®]

- Over 550 individual presentations
- MP3 Audio and Adobe PDFs of the presentations

Highlights DVD-ROM

- Over 80 individual presentations
- Screen capture of presentations are synchronized to MP3 audio recordings
- Perform a keyword search to locate content easily

On Site Discounts Are Available!

Visit the Heart Rhythm OnDemand™ Booths located in
Lobby B and Heart Rhythm Place!

Society Awards Full-Year Research Fellowships

The Heart Rhythm Society honored its Full-Year Research Fellowship Award winners during a breakfast reception yesterday.

The Society has awarded full-year research fellowships in cardiac electrophysiology since 1982. The fellowships are awarded "for the purpose of encouraging research training, either in basic or clinical electrophysiology."

The full-year fellowships are given to researchers early in their careers who seek to gain specialty education and experience. The fellowships are available to individuals who have earned a doctoral degree in medicine, philosophy, osteopathy, or science, or have received equivalent training in biomedical engineering.

Fellowship recipients are expected to use the full-year fellowships to advance their long-term goals in the field of cardiac pacing and electrophysiology.

Abstract presentations

The 2006-2007 HRS Research Fellowship recipients presented their scientific abstracts, covering a variety of areas. Presentations included: Morten B. Thomsen, PhD, "Altered Ion-Current Response to Catecholaminergic Stimulation in Myocytes After Induction of Cardiac Memory;" Kizana Eddy, MBBS, PhD, "Novel Biological Thera-

pies Targeting Cardiac Arrhythmias;" Murali Chiravri, MD, PhD, "The Role of Islet-1 Precursors in the Development and Regeneration of the Cardiac Conduction System;" and Robert D. Winslow, MD, "Atrial Structure and Function Before and After Catheter Ablation for Atrial Fibrillation: A Magnetic Resonance Imaging Study."

Fellowships for 2007-2008

There were seven 2007-2008 fellowships also awarded at the reception. The awardees are: Masatoshi Yamazaki, MD; Michael J. Cutler; Vincent Y. See; Kamilla Kelemen, MD; Mihail G. Chelu, MD; Morton B. Thomsen, PhD; and Jorge E. Massare, MD.

These fellowships are made possible by the continuing support of Boston Scientific Corporation, St. Jude Medical, Medtronic, Inc., and Biotronik, Inc.

The process for selecting the HRS 2008-2009 Fellowships will begin in August 2007. "Every year the Heart Rhythm Society Fellowships are an opportunity to promote research for promising individuals early in their careers," said Kristen Downey, Heart Rhythm Society Education Coordinator. "We encourage all eligible candidates to apply for this opportunity."

**FISCHER
MEDICAL
TECHNOLOGIES**

Manufacturer of the
**"New"
Bloom**

Attendees of the 28th
Annual HRS Scientific
Sessions, welcome to
our corporate home of
Denver, Colorado.

Please visit booth
280, Fischer Medical
Technologies –
manufacturer of the
'new' Bloom and receive
your FREE gift for
saying hello and for your
continued support!



a better
choice
for your
patients

Worldwide
> 400
EP labs use our
cryocatheters

Please join us at booth # 815



CRYOCATH[®]

stop arrhythmias cold

Incoming President Discusses Society Goals for Coming Year

Incoming President Bruce D. Lindsay, MD, FHRS, eyes the coming year with optimism tempered by the realities of a challenging Society agenda as the Heart Rhythm Society moves into its 29th year.

Lindsay said he plans to focus on generating public awareness of sudden cardiac arrest, adoption of the guidelines on catheter ablation of atrial fibrillation, working with The Centers for Medicare & Medicaid Services (CMS) on coding issues and new technologies, and bringing added value and a robust education platform to a growing Society membership.

"My commitment is to fulfill the mission of the organization and move the Strategic Plan forward," Lindsay said. "It is not the President's job to set the agenda. It is the President's job to carry out the strategic mission of the organization." The Heart Rhythm Society accomplishes this objective primarily through its focus on educational programs, health policy/advocacy, the development of guidelines, and membership value.

Education

Lindsay wants to ensure that the

Society's educational programs are continually focusing on cutting edge information and providing members with the latest and best in the field.

"We need to take a hard look at our educational programs — at our annual meeting and other programs we offer — to make sure they are top quality," Lindsay said. "We are a technology-driven industry and meetings are therefore more dependent on technology and more expensive to hold. We need to assess whether we are allocating enough resources for our programs to be the top in the field."

The Society also plans to evaluate educational programs that may not be as effective or compelling as they once were. "In any meeting, some topics generate a lot of excitement, and some have lost their luster," he said. "It's time to consider whether we need to replace these programs with something else."



Bruce D. Lindsay, MD, FHRS

Health policy/advocacy

Lindsay believes the membership may not be aware of all the Society projects that serve the interests of both physicians and patients.

"CMS decided to revise a number of codes regarding ambulatory monitoring; this includes Holter monitors and event monitors," he said. "There are also codes related to Internet-based follow-up of ICDs and pacemakers, and there are some new technologies in development that could affect coding."

Lindsay said the Heart Rhythm Society decided to take the initiative to work with these particular codes. "CMS said it was going to make some changes, and we could either lead the way or they would do it themselves," he said. "We decided that as an organization, it is the Society's responsibility to take on these challenges."

Another important focus on health policy is the Sudden Cardiac Arrest initiative. The purpose of this initiative is to increase public awareness about risk factors for sudden cardiac death, treatments that reduce this risk, and the need for increased funding to improve the understanding of the cascade of pathophysiological events that result in cardiac arrest.

"High-risk" patients account for the minority of sudden cardiac death, and accurate identification of the high-risk patient is difficult. The Heart Rhythm Society supports improved identification of high-risk patients who would benefit from treatment and basic research that explains why "low-risk" patients account for the majority of sudden cardiac arrest victims.

Lindsay also looks forward to the Heart Rhythm Society Consensus Statement on the Surgical and Catheter Ablation of Atrial Fibrillation. This document is the result of the collaboration of many preeminent clinicians, led by Hugh Calkins, MD. The consensus statement addresses all aspects of surgical and catheter ablation, including guidelines for patient selection, methods, avoidance of complications, follow-up care, and trial design.

"This is a comprehensive document," Lindsay said. "It was an international collaborative effort with representation from the American Heart Association, the American College of Cardiology, and European societies."

Membership value

Lindsay, sensitive to the dues-paying membership, said that a fiscally responsible budget has always been a priority for the Heart Rhythm Society.

"We need to continuously reexamine our budget and our process to ensure a responsible budget that gives members the most value for the dues they pay," he said. "We need to look at the services the Society provides to make sure they are cost-effective and that we are reaching members in the areas they need." This includes clinicians who are physicians, allied professionals, and basic scientists, he added.

Lindsay said he looks forward to working with members and society leaders to meet the challenges of the year ahead.

"I have come to appreciate that physicians such as myself are volunteers, and while we put a lot of time and effort into supporting the goals of the Society, we can never do that completely on our own," he said. "We have a highly capable senior staff, and we are lucky to have such a great team in the Society to help us achieve those goals."

CASCADE
REFINING, INC. 2490 South 3200 West • Salt Lake City, Utah 84119
(801) 972-5857

DON'T THROW IT AWAY!

Let us pay you for your scraps.

We want to buy your used EP Catheters, Angioplasty guidewires, and other medical Platinum devices.

Your scraps are very valuable to us; we are willing to **pay you** a premium for these products.

Come visit us today at **Booth #**

974

1.800.955.5857

www.epcatheters.com

Advanced Ablation Course Offers Intensive Training

Education offered by the Heart Rhythm Society does not end at the conclusion of Heart Rhythm 2007 Scientific Sessions. In October, participants can attend the Advanced Ablation Course, which offers additional training in the evolving areas of catheter ablation for complex supraventricular and ventricular arrhythmias.

The course will take place October 14 through October 17 at the Westin Hotel in Chicago. William G. Stevenson, MD; Douglas L. Packer, MD; and David J. Wilber, MD, act as course Co-directors. The course will focus on multimodality ablation for atrial fibrillation and will include comprehensive information about new techniques and technologies.

This intensive four-day course is an opportunity to see first-hand new approaches, techniques, and cutting edge technologies in catheter ablation, including ablation for atrial fibrillation.

The latest methods and techniques for diagnosis and ablation coupled with anatomic insights will be taught using:

- didactic sessions
- case-based workshops
- automated audience response system that provides immediate feedback
- hands-on sessions

For more information on the ablation course, contact the Heart Rhythm Society at (202) 464-3400 or e-mail at info@hrsonline.org.



AFib Summit
May 9-10, 2007

The Heart Rhythm Society would like to thank the following
AFIB SUMMIT SPONSORS
for their valued support at Heart Rhythm 2007

Premier



Executive



CARDIAC RHYTHM MANAGEMENT

A TRADITION OF BREAKTHROUGHS...
CONTRIBUTING TO THE FUTURE



2007
WORLD'S SMALLEST dual chamber pacemaker: REPLY™¹



2005
WORLD'S SMALLEST defibrillator: OVATIO™ DR 6550



2003²
WORLD'S FIRST pacing mode designed to limit unnecessary ventricular pacing: AAsafer™ available in SYMPHONY® pacemakers

2002
WORLD'S FIRST Sensor to optimize AV delay (The Peak Endocardial Acceleration sensor)

1995
WORLD'S FIRST dual chamber defibrillator implant: DEFENDER®

1994
WORLD'S FIRST implant of bi-ventricular pacing system

1981
WORLD'S FIRST microcomputer within a pacemaker

1964
FIRST Sorin Group pacemaker implant

1: Not available in the USA - 2: FDA approval 2005

Exhibitor Listing

AADCO Medical Inc.	978	CardioMedix	775	Greatbatch, Inc..	414	PACE Medical.	238
AAMI/ISO Connector Task Force	679	CardioNet, Inc.	145	Hansen Medical, Inc.	940	Parent Heart Watch	674
Acumen Medical	963	Cardiostim/Reed Expositions France	676	Heart Rhythm Society	352	PGx Health	973
ADInstruments	980	CardioTek BV.	276	Heartlab, an AGFA Company	577	PHILIPS	300
Alta Bates Summit Medical Center	774	Cardiotext.	140	HMP Communications	136	Pressure Products Inc.	338
American Heart Association	573	Cardiovascular Credentialing Int. (CCI)	881	HRA Research	1071, 879	Protech Leded Eyewear Inc.	1041
Arrhythmia Alliance.	281	Cascade Refining Inc.	974	HRS Cyber Center	977	Raytel Cardiac Services.	663
Ascent Healthcare Solutions	1079	CathEffects, Inc.	321	Hypertrophic Cardiomyopathy Assoc. (HCMA)	677	Reliant Pharmaceuticals, Inc.	769
Astellas Pharmaceuticals Inc.	240	CNSystems Medizintechnik GmbH	137	iCardia Healthcare Corporation	876	Research Associates	874
AtriCure, Inc.	152	CONMED Corporation	100	Inovise Medical Inc.	581	Rozinn Electronics, Inc.	1021
Atritech, Inc.	768	Cook Medical	853	Integrated Medical Devices, Inc.	1024	sanofi-aventis.	258
Bard Electrophysiology	653	Cryocath Technologies Inc.	815	Intelwave, LLC	1067	SciMedia	880
Baxter Healthcare Corp.	270	CryoCor, Inc.	272	Lechnologies Research, Inc.	925	Siemens Medical Solutions USA, Inc.	129
Baylis Medical	864	Cuoretech.	976	Lemer Pax	1073	Signalife, Inc.	373
Biomedical Systems	1035	CV Therapeutics	1025	LifeWatch/Instromedix	473	SLACK Incorporated	1072
Biosense Webster, a Johnson & Johnson Co.	615	Daxor Corporation	862	Lippincott Williams & Wilkins	128	Sorin Group	514
Biotronik	322	Dictaphone, a division of Nuance.	878	Mayo Clinical Trial Services.	139	Spacelabs Healthcare.	928
Blackwell Futura	132	eCardio Diagnostics	264	Medical Positioning Inc.	236	Spectranetics	1029
BMEYE B.V.	778	ECG Scanning and Medical Services	1070	Medicomp, Inc.	861	Springer	130
Body Care Resort, Inc.	1068	Elsevier, Inc.	144	Mednet Healthcare Technologies	935	ST Cardio Technologies LLC	579
Boston Atrial Fibrillation Symposium.	223	Endosense S.A.	102	Medtronic, Inc.	601, 901	St. Jude Medical	629
Boston Scientific	335	Enpath Medical, Inc.	1037	Millar Instruments, Inc.	1033	Stereotaxis, Inc.	215, 108
Cambridge Heart, Inc.	245	EP MedSystems, Inc.	101	Mogul Enterprises, Inc.	237	Sudden Arrhythmia Death Syndromes(SADS)	675
Cardiac Arrhythmias Research & Education	680	European Heart Rhythm Association(EHRA)	678	Mortara Instrument.	956	Sudden Cardiac Arrest Association	877
Cardiac Science Corporation	104	Finapres Medical Systems B.V.	969	NorthEast Monitoring, Inc.	241	Survey America & The TouchSource Group	141
Cardima, Inc.	239	Fischer Medical Technologies Inc.	280	Omega Medical Imaging, Inc.	953	SystemsOne LLC.	479
CardioBill, LLC	1069	GE Healthcare	500	OMRON Healthcare	875	Terason	275
CardioComm Solutions Inc.	924			Oscor Inc.	669	Toshiba America Medical Systems, Inc.	779
				Oxford University Press	142	Transoma Medical	379
						TyRx Pharma Inc.	1077
						TZ Medical Inc.	857
						Vascor Medical Corporation	825
						Vascular Solutions	380
						VENICEARRHYTHMIAS.	271
						W B Saunders Mosby	146
						Worldwide Innovations &Technologies, Inc.	763
						XIII World Congress on Cardiac Pacing and Electrophysiology	776
						Zoll Medical Corporation	252

Is Radiation Getting to You?

Block it with



RADPAD[®]

Designed by EP Physicians





WORLDWIDE INNOVATIONS
& TECHNOLOGIES, INC.

Visit us at booth #763



The Heart Rhythm Society would like to thank the following SCIENTIFIC SESSIONS SPONSORS for their valued support at Heart Rhythm 2007

Diamond



Emerald



Sapphire



Ruby

Bard Electrophysiology
Siemens Medical Solutions USA, Inc.
Sorin Group
Stereotaxis, Inc.

Opal

Astellas Pharma USA
Greatbatch, Inc.

Visit LifeWatch in Booth # 473

LifeStar ACT™

REVOLUTIONIZING CARDIAC MONITORING WITH WIRELESS TECHNOLOGY



CAPTURE

arrhythmia onset and escape including AF, Bradycardia, Tachycardia and Pause

PATIENT CONVENIENCE

small, simple sensor and cellular phone monitor

ACT SELECT

Analysis for selected portion (21 days/500 hours) of full disclosure ECG recording

AUTHORIZATION PROCESS

by LifeWatch billing specialists




LifeWatch Services Inc.
Rosemont, IL 60018
Toll Free: 877-774-9846

www.lifewatch.com

Visit Instromedix in Booth # 473

Experience

Innovation in Wireless Patient Monitoring



LifeStar™ Wireless Vital Signs Monitoring System


- Advanced Cellular Handheld
- Wireless Vital Signs Monitors
- Web Viewer




LifeWatch Technologies Inc.
Rosemont, IL 60018
Toll Free: 800-633-3361

www.instromedix.com


Ideas making a difference



Micro Movements.



On Target.



Continuous Confidence.

Now Navigation Ready

EZ STEER™ BI-DIRECTIONAL CATHETERS, WITH PATENTED MICRO-TENSIONING SYSTEM.

The innovative micro-tensioning system in our EZ STEER™ Bi-Directional Catheters gives you unprecedented control over the smallest movements. And CARTO® System compatibility lets you visualize the big picture. Together with our *Set It And Forget It*™ one-time tension adjustment knob—and a host of other advanced features—EZ STEER™ Catheters put a new level of control and confidence close at hand. To learn more please visit www.biosensewebster.com

 **Biosense Webster**®
a *Johnson & Johnson* company

©Biosense Webster, Inc. 2007 All rights reserved.

SCA 360° Raises Awareness of Dangerous Heart Condition

Sudden cardiac arrest (SCA), a leading cause of cardiovascular death in the United States, remains misunderstood, and many patients are not aware of the condition or that they may be at risk.

"SCA is one of the most common reasons that people die in the United States today, yet people confuse it with events such as myocardial infarction, or they believe bypass surgery, stents or angioplasty can reduce their risk," said Bruce L. Wilkoff, MD, Director of Cardiac Pacing and Tachyarrhythmia Devices at The Cleveland Clinic. "SCA is not related to coronary disease or bypass. It is an electrical problem; it is a heart rhythm problem."

SCA, which kills more than 250,000 individuals annually, is a priority for the Society. In response to the issue, HRS developed the SCA 360° initiative to help build awareness of the condition.

Educating the public

The SCA 360° initiative is a comprehensive series of programs to build awareness, educate health care professionals with general cardiologists being the primary target audience, and to increase understanding of SCA. One facet of this is public education through informational brochures, advancing health care provider knowledge of risk factors, and establishment of resource centers.

Wilkoff said it is important for patients to ask their doctors what they can do to assess and reduce their risks.

"Patients with heart failure or who have had a heart attack are at greater risk," he said. "Also, some patients with genetic diseases — not congenital malformations but genetic codes that cause the electrical system to work differently — may be at risk," he explained.

One way of gauging a patient's risk for SCA is to evaluate their ejection fraction, Wilkoff said.

"Normal ejection fraction is 50% to 55%," he said. "If a patient's ejection fraction has decreased to 35% or below, it is clear that these patients

have a substantially increased risk of SCA. At the very least, these patients should be evaluated for SCA."

Although there are identifiable risk factors, Wilkoff said patients generally do not discuss SCA with their doctors.

"Physicians have been treating these problems with effective therapies for years," he said, "but if patients don't know they're at risk, they won't get the treatment they need."

SCA Coalition

At a press conference on Thursday, more than 25 leading heart advocacy groups announced the formation of the Sudden Cardiac Arrest (SCA) Coalition — the first coalition dedicated to advancing increased research, awareness, and educational efforts to address SCA.

The Coalition will urge Congress and the federal agencies involved in

"SCA is not related to coronary disease or bypass. It is an electrical problem; it is a heart rhythm problem."

—Bruce L. Wilkoff, MD

national health policies and programs to devote more resources to greater public awareness of SCA, research, and access to life-saving therapies.

Over the next year, the SCA Coalition will encourage the introduction and passage of an Omnibus bill that, if passed, will provide the Department of Health and Human Services with the resources and the imperative to develop and implement a comprehensive education and research program for SCA.

See The Future Of AF Burden – With Medicomp



- Industry first — ambulatory AF Burden monitoring
- Pre-and post-ablation monitoring measures procedural success
- Ability to monitor patients over many days or weeks

Catch a glimpse of the future at booth 861.

 **MEDICOMP**
Advancing diagnostic cardiology since 1981

sales1@medicompinc.com | 800.23.HEART
www.medicompinc.com

ICD Registry™: Two New Initiatives Advance Goal of Improving Patient Care

Two new initiatives for the ICD Registry™ effort will be launched at Heart Rhythm 2007. The first initiative is to convene both physicians and allied professionals to begin revisions and enhancements targeted to the development of Version 2.0 of the ICD Registry™ data elements and definitions.

"This event marks the beginning of a 12-month effort to assess the current data elements and definitions of the baseline ICD Registry™," said Joel Harder, Manager of Quality Improvement and Outcomes for the Heart Rhythm Society. "The goals of this initiative are to delete data elements that are not useful, add new data elements that are needed, and make minor modifications to data definitions to assure clarity."

New customer service initiatives will be integrated into this effort, such as a new phone system that will improve the speed in providing answers to hospital participants on their concerns. Hospital participants will be asked to complete a questionnaire to provide feedback and ideas for this process at Heart Place.

Workgroup

In addition, a workgroup will meet to implement the new Longitudinal ICD Registry™ study design submitted to the Centers For Medicare & Medicaid Services in April 2007 and approved May 4.

"Although not at the power of a clinical trial, the intent is to define the frequency and appropriateness of ICD device firing therapy and the absolute rates of survival," said Stephen Hammill, Chair of the ICD Registry™ Steering Committee.

The five-year prospective study requires up to 350 physicians randomly selected in the ICD Registry™. Approximately 3,500 Medicare primary prevention patients meeting predetermined criteria will be followed

for three years, and routine follow-up data will be entered into the online tool. An adjudication committee will evaluate the data from a device firing. The primary endpoint will be the first delivery of an appropriate shock or ATP. Participating physicians will be reimbursed for their participation and also will be provided an outcomes report at the end of the study.


Interested participants

Hospital participants who are interested in being involved in the study should contact their Registry Site Manager and answer "yes" to the question, "Would you be willing to participate in any future research study with the ICD Registry?"

Although that does not guarantee

participants' hospitals a slot in the study, it helps the Yale study design coordinators know that the organization is interested in receiving an invitation to participate.

Questions should be directed to Joel Harder, who will be at the ICD Registry™ Booth at Heart Rhythm Place for more information.



Calling All Allied Professionals!

Today

Device Track Sessions

8:00 a.m.–9:30 a.m. Remote Monitoring:
Meeting Workflow Challenges

10:30 a.m.–12:00 p.m. Pharmacology
for AF: Considerations for the Advance
Practitioner

Visit the AP Lounge located
in the Grand Concourse

*COMPLETE EVALUATION AND
CONTACT HOUR CERTIFICATES AT
WWW.HRSONLINE.ORG

Advocacy at Forefront of Health Policy Committee Agenda

The Heart Rhythm Society's Health Policy Committee (HPC) recently undertook a number of advocacy issues addressing heart rhythm topics from the perspective of reimbursement, post-market surveillance, and improvements to the Food and Drug Administration.

Refining coding system

The HPC is taking major steps in the area of reimbursement and coding, according to Bruce Wilkoff, MD, Health Policy Chair. In conjunction with the American Medical Association and the American College of Cardiology, the Society will be suggesting a new coding structure for

the monitoring of pacemakers, implantable defibrillators, biventricular devices, and Holter monitors.

It is the HPC's responsibility to ensure appropriate reimbursement and coding for heart rhythm specialists and to ensure patient access to these treatments, according to Amy Melnick, Vice President of Health Policy.

"When there are new procedures in our field, we make sure there are appropriate clinical practice guideline codes available," she said. "Currently, we are looking to refine and create new codes for patients with implanted pacemakers and defibrillators."

Wilkoff said the HPC addressed the coding issues at the Heart Rhythm 2007 Town Hall Meeting, which was devoted to the larger topic of remote monitoring.

"We discussed the legal and financial issues involved," he said.

Focus on remote monitoring

Wilkoff said the topic of remote monitoring is a top priority for the Health Policy Committee.

"This is an important initiative for us," he said. "We focused our entire Town Hall Meeting on remote monitoring of patients with implantable devices and diagnostic wearable devices," he added.

In September, the committee composed recommendations for device performance of pacemakers and ICDs related to post-market surveillance, Melnick said. She explained that the recommendations involve data communication, device malfunction, and the role of the clinician regarding the devices.

"We are now working to implement these recommendations," she said. "We submitted testimony to the FDA about improvements to the post-market surveillance network, and we are working with Congress to advocate for resources and change in this area."

Coalition for a stronger FDA

The HPC also partnered with the Coalition for a Stronger FDA, joining other agencies that work with the FDA to improve its efficiency.

"The focus of the Coalition is to improve, enhance, and increase appropriations for the FDA so that the agency can do its job better," Melnick said.

Wilkoff said the FDA has addressed the issue of remote monitoring by collaborating with the agencies involved to formulate a "sentinel network" for implantable devices.

"The FDA plans to design a Sentinel Network to provide a way of detecting problems with implantable devices and, hopefully, with drugs as well," he said.

Focus on sudden cardiac awareness

The Heart Rhythm Society has launched a coalition of more than 25 organizations dedicated to the advocacy of legislation to raise awareness of SCA prevention, education, treatment, and research.

According to Wilkoff, "This needs federal attention now, and the Society is in the position to lead this exciting coalition."

The SEARCH FOR SELECTIVITY in Atrial Fibrillation

Atrial-selective ion channel blockade may reduce the risk of ventricular complications in atrial fibrillation.

Ion channels play a crucial role in cardiac electrophysiology.^{1,2} Sodium channels control cell depolarization, the beginning of an action potential.¹ A variety of potassium channels then return the cell to its resting state through repolarization.²

In atrial fibrillation, electrical remodeling of the atria occurs such that repolarization is accelerated and the atrial action potential duration and refractory period are shortened.^{3,6} This results in the disruption of the normal depolarization/repolarization cycle of atrial cells.⁷

Among the many different potassium channels in the atria and ventricles, only **Kur (ultra-rapid delayed rectifier potassium channel)** is predominantly active in the atria.^{1,5,8-11} The Kur channel has not been found to be expressed in the ventricles^{1,5,8-11}; therefore, selective action on this channel in the atria may reduce the risk of ventricular proarrhythmias.^{8,10}

Astellas Pharma US, Inc., is exploring the *selective* blockade of Kur in the atria in order to gain a better understanding of the different pathways involved in atrial fibrillation.

References: 1. Brendel J, Paukert S. *Curr Med Chem Cardiovasc Hematol Agents*. 2003;1:273-287. 2. Oudit GY, Ramirez RJ, Backx PH. In: Zipes DP, Jalife J, eds. *Cardiac Electrophysiology: From Cell to Bedside*. 4th ed. Philadelphia, Pa: Saunders; 2004:19-32. 3. Surawicz B, Knikans TK, eds. *Chou's Electrocardiography in Clinical Practice*. 5th ed. Philadelphia, Pa: Saunders; 2001. 4. Choudhury A, Lip GYH. *Therapy*. 2004;1:111-121. 5. Wijffels MCEF, Crijns HJGM. *J Cardiovasc Electrophysiol*. 2003;14(suppl):S40S47. 6. Van Wagoner DR. In: Zipes DP, Jalife J, eds. *Cardiac Electrophysiology: From Cell to Bedside*. 4th ed. Philadelphia, Pa: Saunders; 2004:375-379. 7. Olgin JE, Zipes DP. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*. 7th ed. Philadelphia, Pa: Elsevier Saunders; 2005:803-863. 8. Knobloch K, Brendel J, Rosenstein B, Bleich M, Busch AE, Wirth KJ. *Med Sci Monit*. 2004;10:BR221-BR228. 9. Goldstein RN, Stambler BS. *Prog Cardiovasc Dis*. 2005;48:193-208. 10. Tamargo J, Caballero R, Gómez R, Valenzuela C, Delpón E. *Cardiovasc Res*. 2004;62:9-33. 11. Decher N, Pirard B, Bundis F, et al. *J Biol Chem*. 2004;279:394-400.



Society Expands IBHRE Exam Prep Courses

The International Board of Heart Rhythm Examiners (IBHRE), formerly NASPE_xAM, is expanding efforts to better meet the needs of members.

The IBHRE, a standard of excellence for cardiac arrhythmia professionals, administers the exam that is recognized as the highest benchmark of professional competency in cardiac pacing, defibrillation, and electrophysiology.

In an effort to further promote the time-honored and well-regarded IBHRE exam, the Heart Rhythm Society introduced the IBHRE Online Exam Prep Course for the Physician last year. This year, the Society introduced an additional course, IBHRE Online Prep Course for the Associated Professional/Cardiac Pacing, to complement the exam for associated professionals.

"The online prep course is an excellent resource and study tool for those preparing for the exam," said Sheri A. Sesay-Tuffour, Executive Director of the IBHRE.

"With 200 questions to work with, it provides an authentic, in-depth experience that is similar to the live exam experience."

Preparatory modules

Sesay-Tuffour said the online prep courses offer a practice module and a timed module. The practice module allows the candidate to gain a thorough understanding of exam questions at their own pace, with feedback and analysis of answers.

"The practice module helps to assess your knowledge base with specific exam content areas," she said. "This method of study is important in broadening your understanding of cardiac arrhythmia practice standards."

Participants have unlimited use of the practice modules for the 12 months prior to the exam and can choose 100 practice questions to work through, Sesay-Tuffour said.

The timed module simulates a real-time test, and there is only

one opportunity to use this feature, she said. "Participants do a final preparatory run through a new set of 100 timed exam questions different from those in the practice module," Sesay-Tuffour explained. "This is as close to taking the actual test as they will get." The prep courses are parallel to the actual exam, with questions comparable to those used in past examinations, she added.

Role of the IBHRE

As an independent body of the Heart Rhythm Society, the IBHRE is "uniquely positioned" to provide those who take the exam with the means to academically or professionally advance in heart rhythm management, Sesay-Tuffour said.

The IBHRE has offered examinations to physicians and associated professionals for more than 20 years. The IBHRE offers three exams: The Examination of Special Competency in Cardiac Pacing and Cardioversion Defibrillation for the

Physician; The Examination of Special Competency in Cardiac Pacing and Cardioversion Defibrillation for the Associated Professional; and The Examination of Special Competency in Cardiac Electrophysiology for the Associated Professional.

In 2008, IBHRE will introduce computer-based testing, Sesay-Tuffour said. IBHRE launched a computer-based schedule at the Heart Rhythm 2007 Scientific Sessions.

Sesay-Tuffour said the IBHRE administers rigorous exams — the average pass rate is 60% — that raise the level of professionalism and credibility in cardiac pacing.

"The exams are not easy, but examinees understand that the knowledge they acquire through testing is critical for optimal patient care. The successful examinee holds the internationally accepted IBHRE recognition with a higher level of proficiency to perform device-related therapies," Sesay-Tuffour said.

Guidant CRT-D Systems from Boston Scientific CRM

Indications and Usage

Guidant Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) are indicated for patients with moderate to severe heart failure (NYHA III/IV) who remain symptomatic despite stable, optimal heart failure drug therapy, and have left ventricular dysfunction (EF \leq 35%) and QRS duration \geq 120 ms.

Contraindications

There are no contraindications for this device.

Warnings

Refer to the product labeling thoroughly before implanting the pulse generator to avoid damage to the system. Such damage can result in injury to, or death of, the patient. Program the pulse generator Tachy Mode to Off during implant, explant or postmortem procedures to avoid inadvertent high voltage shocks. Always have sterile external and internal defibrillator paddles or an equivalent (eg, R2 pads) immediately available during conversion testing. If not terminated in a timely fashion, an induced tachyarrhythmia can result in the patient's death. Ensure that an external defibrillator and medical personnel skilled in CPR are present during post-implant device testing should the patient require external rescue. Do not expose a patient to MRI device scanning. Strong magnetic fields may damage the device and cause injury to the patient. Do not subject a patient with an activated implanted pulse generator to diathermy since diathermy may damage the pulse generator. Do not use atrial-tracking modes in patients with chronic refractory atrial tachyarrhythmias. Tracking of atrial arrhythmias could result in VT or VF. Do not use atrial only modes in patients with heart failure because such modes do not provide CRT. LV lead dislodgment to a position near the atria can result in atrial oversensing and LV pacing inhibition. Physicians should use medical discretion when implanting this device in patients who present with slow VT. Programming therapy for slow monomorphic VT may preclude CRT delivery at faster rates if these rates are in the tachyarrhythmia zones. Do not kink leads. Kinking leads may cause additional stress on the leads, possibly resulting in lead fracture. Do not use defibrillation patch leads with the CRT-D system, or injury to the patient may occur. Do not use the CRT-D with a separate pacemaker system. This combination could result in CRT-D/pacemaker interaction. The emulator is not intended for use as a permanent lead electrode and must be removed from the patient. It is for one-time use only. Do not resterilize.

Precautions

For information on precautions, refer to the following sections of the product labeling: sterilization, storage and handling; implantation and device programming; follow-up testing; pulse generator explant and disposal; environmental and medical therapy hazards; home and occupational environments. Advise patients to avoid sources of electromagnetic interference (EMI) because EMI may cause the pulse generator to deliver inappropriate therapy or inhibit appropriate therapy.

Potential Adverse Events

Potential adverse events from implantation of the Guidant CRT-D system include, but are not limited to, the following: allergic/physical reaction, death, erosion/migration, fibrillation or other arrhythmias, fracture/insulation break (lead or accessory), hematoma/seroma, inappropriate therapy, infection, lead tip deformation and/or breakage, procedure related, psychologic intolerance to an ICD system — patients susceptible to frequent shocks despite antiarrhythmic medical management, random component failure. In rare cases severe complications or device failures can occur.

Refer to the product labeling for specific indications, contraindications, warnings/precautions and adverse events. Rx only.
(Rev. H)

LATITUDE[®] Patient Management System from Boston Scientific CRM

Intended Use

The LATITUDE Patient Management system is intended for use to remotely communicate with a compatible Guidant pulse generator and transfer data to a central database.

Contraindications

The LATITUDE Patient Management system is contraindicated for use with any pulse generator other than a compatible Guidant pulse generator. For contraindications for use related to the Guidant pulse generator, refer to the System Guide for the Guidant pulse generator being interrogated.

Precautions

The LATITUDE system is designed to notify clinicians within 24 hours if new pulse generator alert conditions are detected. However, alert notification cannot occur if:

- The Communicator is unplugged or is not able to connect to the LATITUDE system through an active phone line.
- The pulse generator and the Communicator cannot establish and complete a telemetry session. This session must be initiated by the patient if he or she has a pulse generator that uses inductive telemetry.

Up to two weeks may elapse before LATITUDE detects the events mentioned above and additional time may be required for notification and resolution of the condition.

Adverse Effects

None known.

Refer to the product labeling for specific instructions for use. Rx only.
(Rev. E)

**Boston
Scientific**

Delivering what's next.™

Cardiac Rhythm Management

Boston Scientific Corporation
4100 Hamline Avenue North
St. Paul, MN 55112-5798 USA
Tel: 651-582-4000 Fax: 651-582-4166
Medical Professionals:
1-800-CARDIAC (227-3422)
Patients and Families:
1-866-484-3268
www.bostonscientific.com

Copyright © 2007 by Boston Scientific Corporation or its affiliates.
All rights reserved.

BARD®

Channel Family of Products

BARD®

Channel FX Sheath

The braided shaft of the Bard® Channel FX Sheath provides structural support for enhanced torque and precise catheter control during ablation procedures.




**Bard®
Channel FX
Sheath**

BARD®

Channel Steerable Sheath

The Bard® Channel Steerable Sheath with CurveLock™ Technology allows physicians increased efficiency by maximizing sheath angles for each step in an ablation procedure.



**Bard®
Channel
Steerable
Sheath**

BARD®
ELECTROPHYSIOLOGY
At the heart of arrhythmia therapy™

See Us At Booth 653



360° of care



Information you want, when you want it.



Visit us at
HRS Booth
#335

LATITUDE® Active Monitoring™ gives you the power to impact patient outcomes.

The LATITUDE Patient Management system allows you to identify changes in an implanted device that could leave your patient without life-saving therapy. You or a designated clinician will receive a call from a live customer support person if your patient has an urgent clinical event.

In a documented case¹:

- Physician notified by phone of two urgent clinical events
- Shock therapy might be disabled and device battery was at end of life
- Live technical services call revealed possible device exposure to MRI, confirmed by patient*
- Within 24 hours, device evaluated and returned to normal function with ZOOM LATITUDE® Programmer

For more information or to receive the full case study described above,
call 1-800-CARDIAC (1-800-227-3422).



*MRI scans are not recommended with Boston Scientific/Guidant CRM devices. The physician manuals state, "Do not expose a patient to MRI device scanning. Strong magnetic fields may damage the device and cause injury to the patient."
CONTACT RENEWAL® 3RF System Guide, 357015-003

¹LATITUDE Patient Management system: LATITUDE Active Monitoring™ alerts physician of potential loss of life-saving therapy. Data on file. C7-322-0407. Copyright ©2007 Boston Scientific Corporation

Boston Scientific

Delivering what's next.™